Sensus Healthcare, Inc. (NASDAQ:SRTS – Get Free Report) Director Eric Sachetta acquired 81,575 shares of the firm’s stock in a transaction on Tuesday, November 17th. The shares were acquired at an average price of $2.24 per share, with a total value of $182,728.00. Following the completion of the purchase, the director owned 376,359 shares in the company, valued at approximately $843,044.16. This trade represents a 27.67% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link.
Eric Sachetta also recently made the following trade(s):
- On Monday, August 31st, Eric Sachetta acquired 27,304 shares of Sensus Healthcare stock. The stock was acquired at an average cost of $3.54 per share, for a total transaction of $96,656.16.
- On Friday, August 28th, Eric Sachetta acquired 37,537 shares of Sensus Healthcare stock. The stock was acquired at an average price of $3.44 per share, for a total transaction of $129,127.28.
- On Thursday, August 27th, Eric Sachetta bought 10,925 shares of Sensus Healthcare stock. The shares were acquired at an average cost of $3.18 per share, with a total value of $34,741.50.
- On Wednesday, August 26th, Eric Sachetta bought 9,708 shares of Sensus Healthcare stock. The shares were acquired at an average price of $3.29 per share, with a total value of $31,939.32.
- On Monday, August 24th, Eric Sachetta purchased 34,697 shares of Sensus Healthcare stock. The stock was acquired at an average cost of $3.25 per share, for a total transaction of $112,765.25.
Sensus Healthcare Trading Up 7.7%
SRTS traded up $0.18 during midday trading on Thursday, hitting $2.48. 69,188 shares of the company were exchanged, compared to its average volume of 105,719. The company’s 50 day simple moving average is $2.93 and its 200 day simple moving average is $3.41. The firm has a market capitalization of $40.75 million, a price-to-earnings ratio of -2.56 and a beta of 1.18. Sensus Healthcare, Inc. has a 1-year low of $2.14 and a 1-year high of $5.49.
Sensus Healthcare (NASDAQ:SRTS – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). The company had revenue of $6.00 million during the quarter, compared to analysts’ expectations of $6.61 million. Sensus Healthcare had a negative return on equity of 24.95% and a negative net margin of 96.49%.
Wall Street Analyst Weigh In
A number of equities research analysts have recently commented on the stock. Lake Street Capital dropped their price objective on shares of Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Weiss Ratings cut shares of Sensus Healthcare from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, November 13th. Finally, Alliance Global Partners reissued a “buy” rating on shares of Sensus Healthcare in a report on Monday, August 17th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Sensus Healthcare currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.83.
Read Our Latest Analysis on SRTS
Institutional Trading of Sensus Healthcare
Large investors have recently made changes to their positions in the company. Cetera Investment Advisers acquired a new stake in Sensus Healthcare during the 3rd quarter worth $48,000. EP Wealth Advisors LLC acquired a new stake in shares of Sensus Healthcare in the second quarter valued at about $49,000. Allworth Financial LP purchased a new position in shares of Sensus Healthcare in the third quarter worth about $209,000. BlackRock Inc. purchased a new position in shares of Sensus Healthcare in the second quarter worth about $252,000. Finally, Bank of New York Mellon Corp acquired a new position in Sensus Healthcare during the second quarter worth about $303,000. 25.30% of the stock is currently owned by hedge funds and other institutional investors.
About Sensus Healthcare
Sensus Healthcare, Inc. develops and markets medical devices for the treatment of non-melanoma skin cancer and other skin conditions. Its products use superficial radiation therapy, which delivers low-energy X-rays to targeted areas of the skin. The company’s product portfolio includes the SRT-100 platform and related systems designed for use in clinical settings. Sensus positions these technologies as non-invasive treatment options for conditions including basal and squamous cell skin cancers and keloids.
Recommended Stories
- Five stocks we like better than Sensus Healthcare
- 3 Niche ETFs Are Beating the S&P 500, and Their Strategies Are Anything but Typical
- The Uranium Price Paradox: 5 Investments Facing Very Different Tests in 2027
- Lowe’s Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the Math
- Grounded at 52-Week Lows: When Will Boeing Stock Take Flight?
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
